ML
CRL icon

McAdam LLC’s Charles River Laboratories CRL Stock Holding History

McAdam LLC’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-850
Closed -$230K – 327
2024
Q1 		$230K Sell
850
-72
-8% -$17.2K 0.01% 267
2023
Q4 		$218K Sell
922
-136
-13% -$26.7K 0.02% 254
2023
Q3 		$207K Sell
1,058
-3
-0.3% -$616 0.02% 244
2023
Q2 		$223K Buy
+1,061
New +$211K 0.02% 239
2022
Q2 		– Sell
-832
Closed -$236K – 225
2022
Q1 		$236K Buy
+832
New +$257K 0.02% 185

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

McAdam LLC's CRL Position: Q2 2024 in Review

McAdam LLC sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 850 shares — an estimated $230K sold.

McAdam LLC first reported a position in CRL in Q1 2022 and held it in 5 quarters. The position peaked at $236K in Q1 2022. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • McAdam LLC reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • McAdam LLC sold 850 Charles River Laboratories shares in Q2 2024, an estimated $230K.
  • McAdam LLC first reported a position in Charles River Laboratories in Q1 2022 and held it in 5 quarters.
  • McAdam LLC's Charles River Laboratories position peaked at $236K in Q1 2022.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on McAdam LLC's 13F filing for Q2 2024, filed 24 Jul 2024.